Mechanistically, RNA sequencing (RNA-seq) analysis revealed that tranilast combats hepatic lipid accumulation in NAFLD by deacetylating liver kinase B1 (LKB1) and promoting AMP-activated protein kinase (AMPK) activation. The gene discussed is PRKAA1; the disease is metabolic dysfunction-associated steatotic liver disease.